Новый взгляд на болезнь Альцгеймера через нутригеномику: Путь к парадигме прецизионной медицины. Нарративный обзор
DOI:
https://doi.org/10.53498/eymv8527Ключевые слова:
болезнь Альцгеймера, нутрицевтики, APOE, BDNF, генетический риск, когнитивное снижение, нутригеномика, нутригенетикаАннотация
Болезнь Альцгеймера представляет собой сложное нейродегенеративное заболевание, формирующееся под влиянием генетических, метаболических, воспалительных и экологических факторов. Несмотря на значительный прогресс в изучении патогенеза, терапевтические достижения остаются ограниченными, поскольку заболевание возникает в результате взаимодействия многочисленных взаимосвязанных механизмов, включая накопление амилоид-β, гиперфосфорилирование тау-белка, митохондриальную дисфункцию, окислительный стресс, сосудистые нарушения и хроническое нейровоспаление. Ранняя семейная форма болезни Альцгеймера связана с мутациями в генах APP, PSEN1 и PSEN2, тогда как большинство случаев относится к спорадической поздней форме и определяется полигенными вариациями и факторами образа жизни. Среди генетических факторов наибольший риск связан с аллелем APOE ε4, влияющим на липидный обмен, воспалительные процессы, окислительное повреждение и клиренс амилоида. Варианты, такие как MTHFR C677T, дополнительно изменяют восприимчивость к заболеванию за счет влияния на метаболизм гомоцистеина, метилирование и антиоксидантный баланс. Нутригеномика и нутригенетика предлагают концептуальную основу для изучения взаимодействия между питательными компонентами и генетической архитектурой, определяющего модуляцию ключевых патогенетических путей болезни Альцгеймера. Дефициты питательных веществ, часто сопровождающие когнитивное снижение, усугубляют метаболические нарушения и ускоряют нейродегенерацию, тогда как таргетированные нутрицевтические вмешательства могут улучшать когнитивные и функциональные показатели. Ключевые нутрицевтики, включая омега-3 жирные кислоты, витамины группы B, кверцетин, ресвератрол и бенфотиамин, проявляют нейропротекторные свойства за счет снижения окислительного стресса, подавления воспаления, улучшения митохондриальной функции и активации путей Nrf2, подавления NF-κB и модуляции сигнального пути BDNF. Взаимодействия «ген–диета» указывают на то, что носители генотипов, таких как APOE ε4 или BDNF Val66Met, могут по-разному реагировать на нутритивные стратегии. Интеграция геномных, метаболических и нутриционных данных поддерживает развитие персонализированных нутритивных подходов к профилактике и лечению болезни Альцгеймера. Индивидуализированные вмешательства, соответствующие генетическому профилю, способны уменьшать окислительную и воспалительную нагрузку, усиливать нейропротекторные механизмы и замедлять прогрессирование заболевания.
Библиографические ссылки
1. Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., Hashemi, M., Owji, A. A., Łos, M. J. (2014). Autophagy and apoptosis dysfunction in neurodegenerative disorders. Progress in Neurobiology, 112, 24–49. https://doi.org/10.1016/j.pneurobio.2013.10.004
2. Cetin, S., Knez, D., Gobec, S., Kos, J., Pišlar, A. (2022). Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery. Biomedicine & Pharmacotherapy, 149, 112924. https://doi.org/10.1016/j.biopha.2022.112924
3. Shen, X. N., Niu, L. D., Wang, Y. J., Cao, X. P., Liu, Q., Tan, L., Larbi, A. (2019). Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. Journal of Neurology, Neurosurgery & Psychiatry, 90(5), 590–598. https://doi.org/10.1136/jnnp-2018-319148
4. King, E., O’Brien, J., Donaghy, P., Williams-Gray, C. H., Lawson, R. A., Morris, C. M., Barnett, N., Olsen, K., Martin-Ruiz, C., Burn, D., Yarnall, A. J., Taylor, J.-P., Duncan, G., Khoo, T. K., Thomas, A. J. (2019). Inflammation in mild cognitive impairment due to Parkinson’s disease, Lewy body disease, and Alzheimer’s disease. International Journal of Geriatric Psychiatry, 34(8), 1244–1250. https://doi.org/10.1002/gps.5124
5. Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience, 10, 333–344. https://doi.org/10.1038/nrn2620
6. Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., Zhao, Y. (2020). Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Molecular Neurodegeneration, 15(1), 40. https://doi.org/10.1186/s13024-020-00391-7
7. Serrano-Pozo, A., Frosch, M. P., Masliah, E., Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 1(1), a006189. https://doi.org/10.1101/cshperspect.a006189
8. Deture, M. A., Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer’s disease. Molecular Neurodegeneration, 1491), 32. https://doi.org/10.1186/s13024-019-0333-5
9. Cacace, R., Sleegers, K., Van Broeckhoven, C. (2016). Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimer’s & Dementia, 12, 733–748. https://doi.org/10.1016/j.jalz.2016.01.012
10. Kennedy, A. M., Brown, J., Rossor, M. (2012). The Genetics of Alzheimer’s Disease. Scientifica (Cairo), 2012, 246210. Srinivasan, E., Chandrasekhar, G., Chandrasekar, P., Anbarasu, K., Vickram, A. S., Karunakaran, R., Srikumar, P. S. (2021). Alpha-synuclein aggregation in Parkinson's disease. Frontiers in medicine, 8, 736978. https://doi.org/10.3389/fmed.2021.736978
11. Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., Posthuma, D. (2021). A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nature Genetics, 53(9), 1276–1282. https://doi.org/10.1038/s41588-021-00921-z
12. McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., Bateman, R. J. (2021). The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 16, 49. https://doi.org/10.1186/s13024-021-00467-y
13. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., Roses, A. D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 90(5), 1977–1981. https://doi.org/10.1073/pnas.90.5.1977
14. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., & Schmader, K. E. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7(2), 180–184. https://doi.org/10.1038/ng0694-180
15. Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nature Reviews Neurology, 9(2), 106–118. https://doi.org/10.1038/nrneurol.2012.263
16. Dickson, D. W., Heckman, M. G., Murray, M. E., Soto, A. I., Walton, R. L., Diehl, N. N., van Gerpen, J. A., Uitti, R. J., Wszolek, Z. K., Ertekin-Taner, N., Knopman, D. S., Petersen, R. C., Graff-Radford, N. R., Boeve, B. F., Ross, O. A. (2018). APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 91(12), e1182–e1195. https://doi.org/10.1212/WNL.0000000000006212
17. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J. H., den Heijer, M., Kluijtmans, L. A. J., van den Heuvel, L. P., & Rozen, R. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics, 10(1), 111–113. https://doi.org/10.1038/ng0595-111
18. Huang, X., Qin, X., Yang, W., Liu, L., Jiang, C., Zhang, X., Jiang, S., Bao, H., Su, H., Li, P., He, M., Song, Y., Zhao, M., Yin, D., Wang, Y., Zhang, Y., Li, J., Yang, R., Wu, Y., Hong, K., Wu, Q., Chen, Y., Sun, N., Li, X., Tang, G., Wang, B., Cai, Y., Hou, F. F., Huo, Y., Wang, H., Wang, X., & Cheng, X. (2018). MTHFR gene and serum folate interaction on serum homocysteine lowering: Prospect for precision folic acid treatment. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(3), 679–685. https://doi.org/10.1161/ATVBAHA.117.310211
19. Coppedè, F. (2010). One‑Carbon Metabolism and Alzheimer’s Disease: Focus on Epigenetics. Current Genomics, 11(4), 246–260. https://doi.org/10.2174/138920210791233090
20. Bednarska‑Makaruk, M., Graban, A., Sobczyńska‑Malefora, A., Harrington, D. J., Mitchell, M., Voong, K., Dai, L., Łojkowska, W., Bochyńska, A., Ryglewicz, D., Wiśniewska, A., & Wehr, H. (2016). Homocysteine metabolism and the associations of global DNA methylation with selected gene polymorphisms and nutritional factors in patients with dementia. Experimental Gerontology, 81, 83–91. https://doi.org/10.1016/j.exger.2016.05.002
21. Deep, S. N., Mitra, S., Rajagopal, S., Paul, S., & Poddar, R. (2019). GluN2A-NMDA receptor–mediated sustained Ca²⁺ influx leads to homocysteine-induced neuronal cell death. Journal of Biol. Chemistry, 294(29), 11154–11165. https://doi.org/10.1074/jbc.RA119.008820
22. Esse, R., Barroso, M., Tavares de Almeida, I., & Castro, R. (2019). The contribution of homocysteine metabolism disruption to endothelial dysfunction: state-of-the-art. International Journal of Molecular Sciences, 20(4), 867. https://doi.org/10.3390/ijms20040867
23. Sontag, J.-M., Wasek, B., Taleski, G., Smith, J., Arning, E., Sontag, E., & Bottiglieri, T. (2014). Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice. Frontiers in Aging Neuroscience, 6, 214. https://doi.org/10.3389/fnagi.2014.00214
24. Di Meco, A., Li, J.-G., Barrero, C., Merali, S., Praticò, D. (2018). Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy. Molecular Psychiatry, 24(10), 1696–1706. https://doi.org/10.1038/s41380-018-0062-0
25. Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., Tavernier, B., Letenneur, L., Amouyel, P., European Alzheimer’s Disease Initiative. (2009). Genome‑wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nature Genetics, 41(10), 1094–1099. https://doi.org/10.1038/ng.439
26. Hollingworth, P., Harold, D., Sims, R., et al. (2011). Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nature Genetics, 43, 429–435. https://doi.org/10.1038/ng.803
27. Feringa, F. M., van der Kant, R. (2021). Cholesterol and Alzheimer’s disease: From risk genes to pathological effects. Frontiers in Aging Neuroscience, 13, 690372. https://doi.org/10.3389/fnagi.2021.690372
28. Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023). Role of neuroinflammation in neurodegeneration development. Signal Transduction and Targeted Therapy, 8, 267. https://doi.org/10.1038/s41392-023-01486-5
29. Das, S., Banerjee, P., Jana, S., & Mondal, H. (2025). Unveiling the mechanistic nexus: how micronutrient enrichment shapes brain function, and cognitive health. Frontiers in Molecular Biosciences, 12, 1623547. https://doi.org/10.3389/fmolb.2025.1623547
30. Mierziak, J., Kostyn, K., Boba, A., Czemplik, M., Kulma, A., & Wojtasik, W. (2021). Influence of the bioactive diet components on gene expression regulation. Nutrients, 13(11), 3673. https://doi.org/10.3390/nu13113673
31. Wu, H., Wen, Y., & Guo, S. (2022). Role of nutritional support under clinical nursing path on the efficacy, quality of life, and nutritional status of elderly patients with Alzheimer’s disease. Evidence‑Based Complementary and Alternative Medicine, 2022, Article ID 9712330. https://doi.org/10.1155/2022/9712330
32. Gibas, K. J. (2017). The starving brain: Overfed meets undernourished in the pathology of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Neurochemistry International, 110, 57–68. https://doi.org/10.1016/j.neuint.2017.09.001
33. Cova, I., Clerici, F., Maggiore, L., Pomati, S., Cucumo, V., Ghiretti, R., Galimberti, D., Scarpini, E., Mariani, C., Caracciolo, B. (2016). Body mass index predicts progression of mild cognitive impairment to dementia. Dementia and Geriatric Cognitive Disorders, 41(3–4), 172–180. https://doi.org/10.1159/000444216
34. Stroia, C. M., Pallag, A., Vrânceanu, M., de Lorenzo, D., Grimaldi, K. A., Pallag, C. R., Vindis, K., Bei, D., Burlou‑Nagy, C. (Fati), & Ghitea, T. C. (2025). The Association of VDR, CYP2R1, and GC Gene Polymorphisms, Dietary Intake, and BMI in Regulating Vitamin D Status. Diseases, 13(7), 219. https://doi.org/10.3390/diseases13070219
35. Amin, A. M., Mostafa, H., Khojah, H. M. J. (2023). Insulin resistance in Alzheimer’s disease: The genetics and metabolomics links. Clinica Chimica Acta, 539, 215–236. https://doi.org/10.1016/j.cca.2022.12.016
36. Fenech, M., El‑Sohemy, A., Cahill, L., Ferguson, L. R., French, T. A., Tai, E. S., Milner, J., Koh, W. P., Xie, L., Zucker, M., Buckley, M., Cosgrove, L., Lockett, T., Fung, K. Y. C., Head, R. (2011). Nutrigenetics and nutrigenomics: Viewpoints on the current status and applications in nutrition research and practice. Journal of Nutrigenetics & Nutrigenomics, 4(2), 69–89. https://doi.org/10.1159/000327772
37. de Souza, A. P., Marinho, V., & Marques, M. R. (2025). The fundamental role of nutrients for metabolic balance and epigenome integrity maintenance. Epigenomes, 9(3), 23. https://doi.org/10.3390/epigenomes9030023
38. Xue, B., Waseem, S. M. A., Zhu, Z., Alshahrani, M. A., Nazam, N., Anjum, F., Habib, A. H., Rafeeq, M. M., Nazam, F., & Sharma, M. (2022). Brain‑derived neurotrophic factor: A connecting link between nutrition, lifestyle, and Alzheimer’s disease. Frontiers in Neuroscience, 16, 925991. https://doi.org/10.3389/fnins.2022.925991
39. Fenech, M. (2002). Micronutrients and genomic stability: A new paradigm for recommended dietary allowances (RDAs). Food and Chemical Toxicology, 40(8), 1113–1117. https://doi.org/10.1016/S0278-6915(02)00028-5
40. Botchway, B. O. A., Okoye, F. C., Chen, Y., Arthur, W. E., & Fang, M. (2022). Alzheimer disease: Recent updates on apolipoprotein E and gut microbiome mediation of oxidative stress, and prospective interventional agents. Aging and Disease, 13(1), 87–102. https://doi.org/10.14336/AD.2021.0616
41. Ramesh, B. N., Sathyanarayana Rao, T. S., Prakasam, A., Sambamurti, K., & Jagannatha Rao, K. S. (2010). Neuronutrition and Alzheimer’s disease. Journal of Alzheimer’s Disease, 19(4), 1123–1139. https://doi.org/10.3233/JAD-2010-1312
42. Gülçin, İ. (2025). Antioxidants: a comprehensive review. Archives of Toxicology, 99, 1893–1997.
https://doi.org/10.1007/s00204-025-03997-2
43. Lei, X. G., Zhu, J.-H., Cheng, W.-H., Bao, Y., Ho, Y.-S., Reddi, A. R., Holmgren, A., Arnér, E. S. J. (2015). Paradoxical roles of antioxidant enzymes: Basic mechanisms and health implications. Physiological Reviews, 96(1), 307–364. https://doi.org/10.1152/physrev.00010.2014
44. Fakhri, K. U., Sharma, D., Fatma, H., Yasin, D., Alam, M., Sami, N., Ahmad, F. J., Shamsi, A., & Rizvi, M. A. (2025). The dual role of dietary phytochemicals in oxidative stress: Implications for oncogenesis, cancer chemoprevention, and ncRNA regulation. Antioxidants, 14(6), 620. https://doi.org/10.3390/antiox14060620
45. AbuAlrob, M. (2024). Neuroinflammation in Alzheimer’s disease: Mechanistic insights, pathological implications, and emerging therapeutic strategies. Authorea Preprints. https://doi.org/10.22541/AU.172838938.84403346/V1
46. McGrattan, A. M., McGuinness, B., McKinley, M. C., Kee, F., Passmore, P., Woodside, J. V., & McEvoy, C. T. (2019). Diet and inflammation in cognitive ageing and Alzheimer’s disease. Current Nutrition Reports, 8(2), 53–65. https://doi.org/10.1007/s13668-019-0271-4
47. Griciuc, A., Tanzi, R. E. (2021). The role of innate immune genes in Alzheimer’s disease. Current Opinion in Neurology, 34(2), 228–236. https://doi.org/10.1097/WCO.0000000000000911
48. Li, Y., Xu, H., Wang, H., Yang, K., Luan, J., & Wang, S. (2023). TREM2: Potential therapeutic targeting of microglia for Alzheimer’s disease. Biomedicine & Pharmacotherapy, 165, 115218. https://doi.org/10.1016/j.biopha.2023.115218
49. Gratuze, M., Leyns, C. E. G., Holtzman, D. M. (2018). New insights into the role of TREM2 in Alzheimer’s disease. Molecular Neurodegeneration, 13, 66. https://doi.org/10.1186/s13024-018-0298-9
50. Xue, B., Waseem, S. M. A., Zhu, Z., Alshahrani, M. A., Nazam, N., Anjum, F., Habib, A. H., Rafeeq, M. M., Nazam, F., & Sharma, M. (2022). Brain-derived neurotrophic factor: A connecting link between nutrition, lifestyle, and Alzheimer’s disease. Frontiers in Neuroscience, 16, 925991. https://doi.org/10.3389/fnins.2022.92599
51. Seo, D.-O., & Holtzman, D. M. (2024). Current understanding of the Alzheimer’s disease‑associated microbiome and therapeutic strategies. Experimental & Molecular Medicine, 56(1), 86–94. https://doi.org/10.1038/s12276-023-01146-2
52. Devassy, J. G., Leng, S., Gabbs, M., Monirujjaman, M., Aukema, H. M. (2016). Omega‑3 polyunsaturated fatty acids and oxylipins in neuroinflammation and management of Alzheimer disease. Advances in Nutrition, 7(5), 905–916. https://doi.org/10.3945/an.116.012187
53. Miquel, S., Champ, C., Day, J., Aarts, E., Bahr, B. A., Bakker, M., Bánáti, D., Calabrese, V., Cederholm, T., Cryan, J. F., Dye, L., Farrimond, J. A., Korosi, A., Layé, S., Maudsley, S., Milenkovic, D., Mohajeri, M. H., Sijben, J., Solomon, A., Spencer, J. P. E., Thuret, S., Vanden Berghe, W., Vauzour, D., Vellas, B., Wesnes, K., Willatts, P., Wittenberg, R., & Geurts, L. (2018). Poor cognitive ageing: vulnerabilities, mechanisms and the impact of nutritional interventions. Ageing Research Reviews, 42, 40–55. https://doi.org/10.1016/j.arr.2017.12.004
54. Pistollato, F., Calderón Iglesias, R., Ruiz, R., Aparicio, S., Crespo, J., López, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018). Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: A focus on human studies. Pharmacological Research, 131, 32–43. https://doi.org/10.1016/j.phrs.2018.03.012
55. Minihane, A. M., Vinoy, S., Russell, W. R., Baka, A., Roche, H. M., Tuohy, K. M., Teeling, J. L., Blaak, E. E., Fenech, M., Vauzour, D., McArdle, H. J., Kremer, B. H. A., Sterkman, L., Vafeiadou, K., Benedetti, M. M., Williams, C. M., & Calder, P. C. (2015). Low‑grade inflammation, diet composition and health: Current research evidence and its translation. British Journal of Nutrition, 114(7), 999–1012. https://doi.org/10.1017/S0007114515002093
56. Pistollato, F., Calderón Iglesias, R., Ruiz, R., Aparicio, S., Crespo, J., López, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018). Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: A focus on human studies. Pharmacological Research, 131, 32–43. https://doi.org/10.1016/j.phrs.2018.03.012
57. Huang, S., Rutkowsky, J. M., Snodgrass, R. G., Ono‑Moore, K. D., Schneider, D. A., Newman, J. W., Adams, S. H., & Hwang, D. H. (2012). Saturated fatty acids activate TLR‑mediated proinflammatory signaling pathways. Journal of Lipid Research, 53(9), 2002–2013. https://doi.org/10.1194/jlr.D029546
58. Peres, A. M., Dantas, R. M., Ferreira, A. C., Silveira, A. C. S., Raphaelli, G., Felipe, L., Souza, L., Costa, M., Machado, A., Machado, D., Herrmann, R., de Oliveira, J., Netto, C. A., Wyse, A., Dalmaz, C., & Bast, R. K. S. (2025). Extra virgin olive oil supplementation attenuates hippocampal inflammation in high-fat diet‑induced obesity animals with a depressive phenotype. Brain Behavior and Immunity Integrative, 12, 100137. https://doi.org/10.1016/j.bbii.2025.100137
59. Freitas, H. R., Ferreira, G. D. C., Trevenzoli, I. H., Oliveira, K. D. J., & De Melo Reis, R. A. (2017). Fatty acids, antioxidants and physical activity in brain aging. Nutrients, 9(11), 1263. https://doi.org/10.3390/nu9111263
60. van de Rest, O., Berendsen, A. A. M., Haveman-Nies, A., & de Groot, L. C. P. G. M. (2015). Dietary patterns, cognitive decline, and dementia: A systematic review. Advances in Nutrition, 6(2), 154–168. https://doi.org/10.3945/an.114.007617
61. Jin, Y., Lai, G., Li, S., Lee, J., Chan, V., Lu, Z., Leung, J., Lai, K., Lam, K., Auyeung, T. W., Kwok, T., Chui, K. T., Woo, J., & Lo, K. K.-h. (2025). Adhering to healthy dietary patterns prevents cognitive decline of older adults with sarcopenia: The Mr. OS and Ms. OS Study. Nutrients, 17(19), 3070. https://doi.org/10.3390/nu17193070
62. Stroia, C. M., Ghitea, T. C., Vrânceanu, M., Mureșan, M., Bimbo‑Szuhai, E., Pallag, C. R., & Pallag, A. (2024). Relationship between Vitamin D₃ deficiency, metabolic syndrome and VDR, GC, and CYP2R1 gene polymorphisms. Nutrients, 16(9), 1272. https://doi.org/10.3390/nu16091272
63. Vrânceanu, M., Galimberti, D., Banc, R., Dragoș, O., Cozma‑Petruț, A., Hegheș, S‑C., Voştinaru, O., Cuciureanu, M., Stroia, C. M., Miere, D., & Filip, L. (2022). The anticancer potential of plant‑derived nutraceuticals via the modulation of gene expression. Plants, 11(19), 2524. https://doi.org/10.3390/plants11192524
64. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. https://doi.org/10.1007/s40290-019-00289-w
65. Taylor, J. B., & Triggle, D. J. (Eds.). (2007). Comprehensive Medicinal Chemistry II (2nd ed.). Elsevier. ISBN 978‑0‑08‑044513‑7
66. Chávez‑Castillo, M., Gotera, M. P., Duran, P., Díaz, M. P., Nava, M., Cano, C., Díaz‑Camargo, E., Cano, G., Cano, R., Rivera‑Porras, D., & Bermúdez, V. (2025). Neuroprotective role of omega‑3 fatty acids: Fighting Alzheimer’s disease. Molecules, 30(15), 3057. https://doi.org/10.3390/molecules30153057
67. Ajith, T. A. (2018). A recent update on the effects of omega‑3 fatty acids in Alzheimer’s disease. Current Clinical Pharmacology, 13(4), 252–260. https://doi.org/10.2174/1574884713666180807145648
68. Heras‑Sandoval, D., & Pedraza‑Chaverri, J., & Pérez‑Rojas, J. M. (2016). Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer’s disease. Journal of Neuroinflammation, 13, 61. https://doi.org/10.1186/s12974-016-0525-7
69. Sala‑Vila, A., Satizabal, C. L., Tintle, N., Melo van Lent, D., Vasan, R. S., Beiser, A. S., Seshadri, S., & Harris, W. S. (2022). Red blood cell DHA is inversely associated with risk of incident Alzheimer’s disease and all‑cause dementia: Framingham Offspring Study. Nutrients, 14(12), 2408. https://doi.org/10.3390/nu14122408
70. Otsuka, R., Tange, C., Nishita, Y., Kato, Y., Imai, T., Ando, F., & Shimokata, H. (2014). Serum docosahexaenoic and eicosapentaenoic acid and risk of cognitive decline over 10 years among elderly Japanese. European Journal of Clinical Nutrition, 68(4), 503–509. https://doi.org/10.1038/ejcn.2013.264
71. Ebright, B., Duro, M. V., Chen, K., Louie, S., & Yassine, H. N. (2024). Effects of APOE4 on omega‑3 brain metabolism across the lifespan. Trends in Endocrinology & Metabolism, 35(8), 745–757. https://doi.org/10.1016/j.tem.2024.03.003
72. van de Rest, O., Wang, Y., Barnes, L. L., Tangney, C., Bennett, D. A., & Morris, M. C. (2016). APOE ε4 and the associations of seafood and long‑chain omega‑3 fatty acids with cognitive decline. Neur, 86(22), 2063–2070. https://doi.org/10.1212/WNL.0000000000002719
73. Whalley, L. J., Deary, I. J., Starr, J. M., Wahle, K. W., Rance, K. A., Bourne, V. J., & Fox, H. C. (2008). n‑3 fatty acid erythrocyte membrane content, APOE ε4, and cognitive variation: An observational follow‑up study in late adulthood. American Journal of Clinical Nutrition, 87(2), 449–454. https://doi.org/10.1093/ajcn/87.2.449
74. Liu, H., Yang, M., Li, G. M., Qiu, Y., Zheng, J., Du, X., Wang, J.‑L., & Liu, R.‑W. (2010). The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: A meta‑analysis. Journal of Neurol Sciences, 294(1–2), 74–80. https://doi.org/10.1016/j.jns.2010.04.00
75. Clarke, R., Bennett, D., Parish, S., Lewington, S., Skeaff, M., Eussen, S. J.P.M., Lewerin, C., Stott, D. J., Armitage, J., Hankey, G. J., Lonn, E., Spence, J. D., Galan, P., de Groot, L. C. P. G. M., Halsey, J., Dangour, A. D., Collins, R., & Grodstein, F. (2014). Effects of homocysteine lowering with B vitamins on cognitive aging: meta‑analysis of 11 trials with cognitive data on 22,000 individuals. American Journal of Clinical Nutrition, 100(2), 657–666. https://doi.org/10.3945/ajcn.113.076349
76. Boldyrev, A., Bryushkova, E., Mashkina, A., Vladychenskaya, E. (2013). Why is homocysteine toxic for the nervous and immune systems? Current Aging Science, 6(1), 29–36. https://doi.org/10.2174/18746098112059990007
77. Liu, H., Yang, M., Li, G. M., Qiu, Y., Zheng, J., Du, X., Wang, J.‑L., & Liu, R.‑W. (2010). The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: A meta‑analysis. Journal of Neurological Sciences, 294(1–2), 74–80. https://doi.org/10.1016/j.jns.2010.04.001
78. Román, G. C., Mancera‑Páez, O., & Bernal, C. (2019). Epigenetic factors in late‑onset Alzheimer’s disease: MTHFR and CTH gene polymorphisms, metabolic transsulfuration and methylation pathways, and B vitamins. International Journal of Molecular Sciences, 20(2), 319. https://doi.org/10.3390/ijms20020319
79. Spence, J. D., Yi, Q., & Hankey, G. J. (2017). B vitamins in stroke prevention: time to reconsider. The Lancet Neurology, 16(9), 750–760. https://doi.org/10.1016/S1474-4422(17)30238-0
80. Ułamek‑Kozioł, M., Pluta, R., Bogucka‑Kocka, A., Januszewski, S., Kocki, J., & Czuczwar, S. J. (2016). Brain ischemia with Alzheimer phenotype dysregulates Alzheimer’s disease‑related proteins. Pharmacological Reports, 68(3), 582–591. https://doi.org/10.1016/j.pharep.2016.01.006
81. Carrillo‑Martinez, E. J., Flores‑Hernández, F. Y., Salazar‑Montes, A. M., Nario‑Chaidez, H. F., & Hernández‑Ortega, L. D. (2024). Quercetin, a flavonoid with great pharmacological capacity. Molecules, 29(5), 1000. https://doi.org/10.3390/molecules29051000
82. Aghababaei, F., & Hadidi, M. (2023). Recent advances in potential health benefits of quercetin. Pharmaceuticals, 16(7), 1020. https://doi.org/10.3390/ph16071020
83. Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., & Sugimoto, H. (2008). Flavonols and flavones as BACE-1 inhibitors: Structure–activity relationship in cell‑free, cell‑based and in silico studies reveal novel pharmacophore features. Biochimica et Biophysica Acta (BBA) – General Subjects, 1780(5), 819–825. https://doi.org/10.1016/j.bbagen.2008.01.017
84. Yu, Z., Wei, X., Dai, L., Ma, W., Li, W., Li, X., & Han, X.-L. (2025). Dual binding modes of Quercetin to BSA: Insights from spectroscopy and molecular simulations in amyloid suppression. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 348(Pt 2), 127093. https://doi.org/10.1016/j.saa.2025.127093
85. Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2024). Exploring the potential of quercetin in Alzheimer’s disease: Pharmacodynamics, pharmacokinetics, and nanodelivery systems. Brain Research, 1834, 148905. https://doi.org/10.1016/j.brainres.2024.148905
86. Sabogal‑Guáqueta, A. M., Muñoz‑Manco, J. I., Ramírez‑Pineda, J. R., Lamprea‑Rodríguez, M., Osorio, E., & Cardona‑Gómez, G. P. (2015). The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice. Neuropharmacology, 93, 134–145. https://doi.org/10.1016/j.neuropharm.2015.01.027
87. Wang, D.-M., Li, S.-Q., Wu, W.-L., Zhu, X.-Y., Wang, Y., & Yuan, H.-Y. (2014). Effects of long-term treatment with quercetin on cognition and mitochondrial function in a mouse model of Alzheimer’s disease. Neurochemical Research, 39(8), 1533–1543. https://doi.org/10.1007/s11064-014-1343-x
88. Karimipour, M., Rahbarghazi, R., Tayefi, H., Shimia, M., Ghanadian, M., & Mahmoudi, J. (2019). Quercetin promotes learning and memory performance concomitantly with neural stem/progenitor cell proliferation and neurogenesis in the adult rat dentate gyrus. International Journal of Developmental Neuroscience, 74, 18–26. https://doi.org/10.1016/j.ijdevneu.2019.02.005
89. Zhang, X., Hu, J., Zhong, L., Wang, N., Yang, L., Liu, C.-C., Li, H., Wang, X., Zhou, Y., Zhang, Y., Xu, H., Bu, G., & Zhuang, J. (2016). Quercetin stabilizes apolipoprotein E and reduces brain Aβ levels in amyloid model mice. Neuropharmacology, 108, 179–192. https://doi.org/10.1016/j.neuropharm.2016.04.032
90. Bukhari, S. N. A. (2022). Dietary polyphenols as therapeutic intervention for Alzheimer’s disease: A mechanistic insight. Antioxidants, 11, 554. https://doi.org/10.3390/antiox11030554
91. Quadros Gomes, B. A., Bastos Silva, J. P., Rodrigues Romeiro, C. F., Monteiro dos Santos, S., Azulay Rodrigues, C., Rodrigues Gonçalves, P., Sakai, J. T., Santos Mendes, P. F., Pompeu Varela, E. L., & Monteiro, M. C. (2018). Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: Role of SIRT1. Oxidative Medicine and Cellular Longevity, 2018, 8152373. https://doi.org/10.1155/2018/8152373
92. Alarcón de la Lastra, C., & Villegas, I. (2007). Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. Biochemical Society Transactions, 35(5), 1156–1160. https://doi.org/10.1042/BST0351156
93. Ugusman, A., Zakaria, Z., Hui, C. K., & Nor Anita Megat Mohd Nordin, N. A. M. M. (2011). Piper sarmentosum inhibits ICAM‑1 and Nox4 gene expression in oxidative stress‑induced human umbilical vein endothelial cells. BMC Complementary and Alternative Medicine, 11, 31. https://doi.org/10.1186/1472-6882-11-31
94. Ungvari, Z., Bagi, Z., Feher, A., Recchia, F. A., Sonntag, W. E., Pearson, K., de Cabo, R., & Csiszar, A. (2010). Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. American Journal of Physiology – Heart and Circulatory Physiology, 299(1), H18–H24. https://doi.org/10.1152/ajpheart.00260.2010
95. Chen, Z.-J., Yang, Y.-F., Zhang, Y.-T., & Yang, D.-H. (2018). Dietary total prenylflavonoids from the fruits of Psoralea corylifolia L. prevents age‑related cognitive deficits and down‑regulates Alzheimer’s markers in SAMP8 mice. Molecules, 23(1), 196. https://doi.org/10.3390/molecules23010196
96. Sathya, M., Moorthi, P., Premkumar, P., Kandasamy, M., Jayachandran, K. S., & Anusuyadevi, M. (2017). Resveratrol intervenes cholesterol‑ and isoprenoid‑mediated amyloidogenic processing of AβPP in familial Alzheimer’s disease. Journal of Alzheimer’s Disease, 60(suppl. 1), S3–S23. https://doi.org/10.3233/JAD‑161034
97. Zhang, M., & Tang, Z. (2023). Therapeutic potential of natural molecules against Alzheimer’s disease via SIRT1 modulation. Biomedicine & Pharmacotherapy, 161, 114474. https://doi.org/10.1016/j.biopha.2023.114474
98. Yan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., Yu, C.-L., Wong, V. K.-W., Li, H., Li, M., Zhou, X.-G., Qin, D.-L., & Wu, A.-G. (2022). Dietary plant polyphenols as the potential drugs in neurodegenerative diseases: current evidence, advances, and opportunities. Oxidative Medicine and Cellular Longevity, 2022, 5288698. https://doi.org/10.1155/2022/5288698
99. Zhu, L., Lu, F., Zhang, X., Liu, S., & Mu, P. (2022). SIRT1 is involved in the neuroprotection of pterostilbene against amyloid β₍25–35₎‑induced cognitive deficits in mice. Frontiers in Pharmacology, 13, 877098. https://doi.org/10.3389/fphar.2022.877098
100. Karthick, C., Periyasamy, S., Jayachandran, K. S., & Anusuyadevi, M. (2016). Intrahippocampal administration of ibotenic acid induced cholinergic dysfunction via NR2A/NR2B expression: Implications of resveratrol against Alzheimer disease pathophysiology. Frontiers in Molecular Neuroscience, 9, 28. https://doi.org/10.3389/fnmol.2016.00028
101. Pomero, F., Molinar Min, A., La Selва, M., Allione, A., Molinatti, G. M., & Porta, M. (2001). Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetologica, 38(3), 135–138. https://doi.org/10.1007/s005920100171
102. Bozic, I., & Lavrnja, I. (2023). Thiamine and benfotiamine: Focus on their therapeutic potential. Heliyon, 9, e21839. https://doi.org/10.1016/j.heliyon.2023.e21839
103. Tapias, V., Jainuddin, S., Ahuja, M., Stack, C., Elipenahli, C., Vignisse, J., Gerges, M., Starkova, N., Xu, H., Starkov, A. A., … & Przedborski, S. (2018). Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Human Molecular Genetics, 27(16), 2874–2892. https://doi.org/10.1093/hmg/ddy201
104. Pan, X., Gong, N., Zhao, J., Yu, Z., Gu, F., & Chen, J. (2010). Powerful beneficial effects of benfotiamine on cognitive impairment and β‑amyloid deposition in amyloid precursor protein/presenilin‑1 transgenic mice. Brain, 133(5), 1342–1351. https://doi.org/10.1093/brain/awq069
105. Sambon, M., Napp, A., Demelenne, A., Vignisse, J., Wins, P., Fillet, M., & Bettendorff, L. (2019). Thiamine and benfotiamine protect neuroblastoma cells against paraquat and β-amyloid toxicity by a coenzyme‑independent mechanism. Heliyon, 5, e01710. https://doi.org/10.1016/j.heliyon.2019.e01710
106. Vignisse, J., Sambon, M., Gorlova, A., Pavlov, D., Caron, N., Malgrange, B., Shevtsova, E., Svistunov, A., Anthony, D. C., Markova, N., Bazhenova, N., Coumans, B., Lakaye, B., Wins, P., Strekalova, T., & Bettendorff, L. (2017). Thiamine and benfotiamine prevent stress‑induced suppression of hippocampal neurogenesis in mice exposed to predation without affecting brain thiamine diphosphate levels. Molecular and Cellular Neuroscience, 82, 126–136. https://doi.org/10.1016/j.mcn.2017.05.005
107. Tapias, V., Jainuddin, S., Ahuja, M., Stack, C., Elipenahli, C., Vignisse, J., Gerges, M., Starkova, N., Xu, H., Starkov, A. A., Bettendorff, L., Hushpulian, D. M., Smirnova, N. A., Gazaryan, I. G., Kaidery, N. A., Wakade, C., Calingasan, N. Y., Thomas, B., Gibson, G. E., Dumont, M., & Beal, M. F. (2018). Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Human Molecular Genetics, 27(16), 2874–2892. https://doi.org/10.1093/hmg/ddy201
108. Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak‑Vance, M. A., Goldgaber, D., & Roses, A. D. (1993). Increased amyloid β‑peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late‑onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 90(20), 9649–9653. https://doi.org/10.1073/pnas.90.20.9649
109. Deo, P., Dhillon, V. S., Chua, A., Thomas, P., & Fenech, M. (2020). APOE ε4 carriers have a greater propensity to glycation and sRAGE which is further influenced by RAGE G82S polymorphism. The Journals of Gerontology: Series A, 75(10), 1899–1905. https://doi.org/10.1093/gerona/glz259
110. Park, H., Ni, M., & Le, Y. (2025). Neuroinflammation and nutrition in Alzheimer’s disease. Frontiers in Neurology, 16, 1622571. https://doi.org/10.3389/fneur.2025.1622571
111. Xue, B., Waseem, S. M. A., Zhu, Z., Alshahrani, M. A., Nazam, N., Anjum, F., Habib, A. H., Rafeeq, M. M., Nazam, F., & Sharma, M. (2022). Brain‑derived neurotrophic factor: A connecting link between nutrition, lifestyle, and Alzheimer’s disease. Frontiers in Neuroscience, 16, 925991. https://doi.org/10.3389/fnins.2022.925991
112. Yassine, H. N., & Finch, C. E. (2020). APOE alleles and diet in brain aging and Alzheimer’s disease. Frontiers in Aging Neuroscience, 12, 150. https://doi.org/10.3389/fnagi.2020.00150
113. Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., Lindström, J., Mangialasche, F., Paajanen, T., Pajala, S., Peltonen, M., Rauramaa, R., Stigsdotter‑Neely, A., Strandberg, T. E., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2015). A 2‑year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at‑risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5
